NCT05065047View on ClinicalTrials.gov

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Given by IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER